Answers are grounded in this paper and cite their sources.
Ischemic stroke remains a leading cause of mortality and long-term disability, with current reperfusion therapies limited by narrow therapeutic windows and inability to promote sustained neurovascular repair. Here, we developed YZD-27, a rationally designed Tanshinone IIA (TSA) derivative with improved druggability, and show that it remains therapeutically effective when administered up to 24 h after ischemic injury in transient and permanent middle cerebral artery occlusion (tMCAO and dMCAO) mouse models. Single-cell RNA sequencing (scRNA-seq) and cell-cell communication analysis revealed broad cellular responses to YZD-27 and identified fibronectin-1 (Fn1)/syndecan-4 (Sdc4) as a predicted endothelia-fibroblast ligand-receptor interaction. Mechanistically, YZD-27 directly binds forkhead box protein C2 (Foxc2), enhances its protein stability by limiting proteasomal degradation, and increases its occupancy at the Sdc4 promoter, thereby repressing Sdc4 transcription in fibroblast. Fibroblast-conditioned medium experiments further supported a role for Foxc2/Sdc4 regulation in modulating endothelial barrier-related protein expression. These findings identify Foxc2/Sdc4 signaling as a regulatory mechanism associated with the therapeutic effects of YZD-27, and establish YZD-27 as a promising neurovascular therapeutic candidate for ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: